Vaccination with Killed but Metabolically Active Over-expressing Hemagglutinin Elicits Neutralizing Antibodies to H1N1 Swine Origin Influenza A Virus

Overview

Journal J Nat Sci

Date 2017 May 12

PMID 28492063

Authors

Pei-Feng Liu

Yanhan Wang

Yu-Tsueng Liu

Chun-Ming Huang

Affiliations

Soon will be listed here.

Abstract

There is a need for a fast and simple method for vaccine production to keep up with the pace of a rapidly spreading virus in the early phases of the influenza pandemic. The use of whole viruses produced in chicken eggs or recombinant antigens purified from various expression systems has presented considerable challenges, especially with lengthy processing times. Here, we use the killed but metabolically active (KBMA) () to harbor the hemagglutinin (HA) of swine origin influenza A (H1N1) virus (S-OIV) San Diego/01/09 (SD/H1N1-S-OIV). Intranasal vaccination of mice with KBMA SD/H1N1-S-OIV HA without adding exogenous adjuvants provoked detectable neutralizing antibodies against the virus-induced hemagglutination within three weeks. Boosting vaccination enhanced the titers of neutralizing antibodies, which can decrease viral infectivity in Madin-Darby canine kidney (MDCK) cells. The antibodies were found to specifically neutralize the SD/H1N1-S-OIV-, but not seasonal influenza viruses (H1N1 and H3N2), -induced hemagglutination. The use of KBMA as an egg-free system to produce anti-influenza vaccines makes unnecessary the rigorous purification of an antigen prior to immunization, providing an alternative modality to combat influenza virus in future outbreaks.

References

Lankowski A, Hohmann E . Killed but metabolically active Salmonella typhimurium: application of a new technology to an old vector. J Infect Dis. 2007; 195(8):1203-11. DOI: 10.1086/512618. View

Alekshun M, Levy S . Commensals upon us. Biochem Pharmacol. 2006; 71(7):893-900. DOI: 10.1016/j.bcp.2005.12.040. View

Kuroda K, Hauser C, Rott R, Klenk H, DOERFLER W . Expression of the influenza virus haemagglutinin in insect cells by a baculovirus vector. EMBO J. 1986; 5(6):1359-65. PMC: 1166948. DOI: 10.1002/j.1460-2075.1986.tb04367.x. View

Bren L . West Nile virus: reducing the risk. FDA Consum. 2003; 37(1):20-7. View

Avril M, Hathaway M, Srivastava A, Dechavanne S, Hommel M, Beeson J . Antibodies to a full-length VAR2CSA immunogen are broadly strain-transcendent but do not cross-inhibit different placental-type parasite isolates. PLoS One. 2011; 6(2):e16622. PMC: 3034725. DOI: 10.1371/journal.pone.0016622. View

Fedson D . NEW technologies for meeting the global demand for pandemic influenza vaccines. Biologicals. 2008; 36(6):346-9. DOI: 10.1016/j.biologicals.2008.07.001. View

Liu P, Nakatsuji T, Zhu W, Gallo R, Huang C . Passive immunoprotection targeting a secreted CAMP factor of Propionibacterium acnes as a novel immunotherapeutic for acne vulgaris. Vaccine. 2011; 29(17):3230-8. PMC: 3388602. DOI: 10.1016/j.vaccine.2011.02.036. View

Kuroda K, Groner A, Frese K, Drenckhahn D, Hauser C, Rott R . Synthesis of biologically active influenza virus hemagglutinin in insect larvae. J Virol. 1989; 63(4):1677-85. PMC: 248419. DOI: 10.1128/JVI.63.4.1677-1685.1989. View

Yuki Y, Kiyono H . Mucosal vaccines: novel advances in technology and delivery. Expert Rev Vaccines. 2009; 8(8):1083-97. DOI: 10.1586/erv.09.61. View

10.

Sipo I, Knauf M, Fechner H, Poller W, Planz O, Kurth R . Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV). Vaccine. 2011; 29(8):1690-9. DOI: 10.1016/j.vaccine.2010.12.037. View

11.

Watts P, Smith A . Re-formulating drugs and vaccines for intranasal delivery: maximum benefits for minimum risks?. Drug Discov Today. 2010; 16(1-2):4-7. DOI: 10.1016/j.drudis.2010.11.001. View

12.

Henkin R . Intranasal delivery to the brain. Nat Biotechnol. 2011; 29(6):480. DOI: 10.1038/nbt.1866. View

13.

Brockstedt D, Bahjat K, Giedlin M, Liu W, Leong M, Luckett W . Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat Med. 2005; 11(8):853-60. DOI: 10.1038/nm1276. View

14.

Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A . Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis. 2009; 200(6):841-8. DOI: 10.1086/605505. View

15.

Sander L, Davis M, Boekschoten M, Amsen D, Dascher C, Ryffel B . Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. Nature. 2011; 474(7351):385-9. PMC: 3289942. DOI: 10.1038/nature10072. View

16.

Kistner O, Barrett P, Mundt W, Reiter M, Dorner F . Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine. 1998; 16(9-10):960-8. DOI: 10.1016/s0264-410x(97)00301-0. View

17.

Girard M, Tam J, Assossou O, Kieny M . The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine. 2010; 28(31):4895-902. DOI: 10.1016/j.vaccine.2010.05.031. View

18.

Khurana S, Verma S, Verma N, Crevar C, Carter D, Manischewitz J . Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS One. 2010; 5(7):e11548. PMC: 2902520. DOI: 10.1371/journal.pone.0011548. View

19.

Olsen B, Munster V, Wallensten A, Waldenstrom J, Osterhaus A, Fouchier R . Global patterns of influenza a virus in wild birds. Science. 2006; 312(5772):384-8. DOI: 10.1126/science.1122438. View

20.

Schwarzer J, Rapp E, Hennig R, Genzel Y, Jordan I, Sandig V . Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin. Vaccine. 2009; 27(32):4325-36. DOI: 10.1016/j.vaccine.2009.04.076. View